The Emirates Drug Establishment announced the conditional approval for the new use of Ultomiris, also known as ravulizumab, which is intended for adults with primary immunoglobulin A nephropathy who face a high risk of disease worsening. This intravenous therapy aims to lower protein levels in the urine, a key sign of advancing kidney damage, according to the regulator’s statement. The decision follows the medicine’s initial registration in the UAE in 2022 for multiple rare diseases, expanding its available indications in the country.
Primary immunoglobulin A nephropathy is an immune-mediated condition that develops when immune proteins accumulate in kidney tissue, triggering inflammation and a gradual loss of function, a review in Seminars in Nephrology described. The disease carries a global incidence of roughly 2.5 cases per 100,000 people each year, though biopsy data show it accounts for between 25 and 50 percent of primary glomerular disease cases across East Asian countries while remaining less frequent in North America and Africa. Elevated urinary protein serves as a major predictor of progression toward more severe outcomes including potential kidney failure, the Emirates Drug Establishment noted.
Interim results from the I CAN Phase 3 trial, published in the New England Journal of Medicine, found that Ultomiris delivered a 46.6 percent drop in the 24-hour urine protein-to-creatinine ratio at week 34 from baseline compared with a 5.6 percent reduction in the placebo arm. This produced a 43.4 percent placebo-adjusted advantage, with benefits emerging by week 10 and holding steady through the assessment period across varied patient subgroups. Safety data indicated adverse events in 69.5 percent of those receiving Ultomiris versus 75.8 percent on placebo, with no meningococcal infections or fatalities recorded in either group.
Dr Ruqaya Al Bastaki, acting executive director of the medical products regulation sector at the Emirates Drug Establishment, stated that the body’s evaluation process rests on detailed scientific review while maintaining stringent standards for safety, quality and effectiveness. The Emirates Drug Establishment emphasised the value of prompt diagnosis together with consistent tracking of kidney performance and urinary protein alongside strict compliance with physician-directed regimens to limit complications. Such measures form part of a broader effort to address this form of kidney disease effectively in clinical practice.
Sameh El Fangary, Gulf Cluster President at AstraZeneca, described the conditional approval as a meaningful advance that broadens therapeutic choices for individuals living with immunoglobulin A nephropathy. He indicated that the company anticipates ongoing cooperation with UAE authorities to facilitate access for suitable patients, enhance clinical results and raise overall standards of care, according to the announcement. The conditional status requires continued evidence gathering to affirm sustained benefits under real-world conditions.
This regulatory action supports the objectives of the We the UAE 2031 vision by reinforcing the nation’s standing in healthcare and pharmaceutical innovation while promoting research and development, the Emirates Drug Establishment said in its statement. It also advances the establishment’s goal of building a forward-looking regulatory environment that draws on international best practices to accelerate availability of new therapies without compromising quality. The Emirates Drug Establishment first registered Ultomiris in 2022, providing a foundation for this latest expansion in approved uses.
ع